Literature DB >> 30456637

Correction of Tear Trough Deformity Using Autologous Fibroblast Combined with Keratin: New Soft Tissue Filler.

Wenshan Xing1, Chen Zhang2, Jiao Zhang1, Qingguo Zhang3.   

Abstract

OBJECTIVE: To evaluate the effectiveness and safety of autologous fibroblasts combined with keratin gel for tear trough deformity rectification as injectable soft tissue filler.
MATERIALS AND METHODS: The new injectable soft tissue filler was derived from autologous fibroblasts and keratin gel. A total of 35 patients received treatment of this filler injection for tear trough deformity rectification. All the patients were followed up, and the clinical features including photographs and satisfaction were collected and assessed at 1, 3, 6, 12 and 24 months after injection. The efficacy of each patient was evaluated independently by blinded evaluators at different time points. All patients consented to publish identifiable photographs in this study.
RESULTS: Tear trough deformity was improved even at 18-24 months post-injection. No severe adverse effects were observed resulting from the filler injection.
CONCLUSION: Combination of autologous fibroblasts and keratin is efficient and safe for correction of the tear trough deformity with long-term satisfaction and desirable result. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

Entities:  

Keywords:  Blepharoplasty; Esthetics; Fibroblasts; Keratins

Mesh:

Substances:

Year:  2018        PMID: 30456637     DOI: 10.1007/s00266-018-1259-y

Source DB:  PubMed          Journal:  Aesthetic Plast Surg        ISSN: 0364-216X            Impact factor:   2.326


  1 in total

1.  Autologous Biological Vitamin-C-added (ABC) Filler for Facial Volume Restoration.

Authors:  Kadri Ozer; Oguz Atan; Özlem Çolak
Journal:  Aesthetic Plast Surg       Date:  2021-05-10       Impact factor: 2.708

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.